Tag Archive for: CAR-T cell therapy

Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

/in

Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM  London, UK and Chicago, IL – 15 December 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, and Syenex, an open-science genetic medicines platform company, today announced a strategic collaboration […]

Read more

Astraveus opens path to accessible cell therapies with first ever end-to-end microfluidic CAR-T production

/in

Paris, France, 9 January 2025 – Astraveus SAS (“Astraveus” or the “Company”), the Benchtop Cell Factory company, today announces the first ever successful end-to-end production of CAR-T cells within a microfluidic benchtop system. Using its fully automated Lakhesys Benchtop Cell FactoryTM, Astraveus has been able to demonstrate the potential of its unique microfluidic cell therapy processing […]

Read more

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

/in

London, UK – 18 July 2023 – Leucid Bio (“Leucid” or the “Company”), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect. Mr. Petti has […]

Read more